List of Excipients in Branded Drug LEADER OMEPRAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cardinal Health	LEADER OMEPRAZOLE	omeprazole	70000-0356	CARNAUBA WAX
Cardinal Health	LEADER OMEPRAZOLE	omeprazole	70000-0356	FERRIC OXIDE RED
Cardinal Health	LEADER OMEPRAZOLE	omeprazole	70000-0356	FERRIC OXIDE YELLOW
Cardinal Health	LEADER OMEPRAZOLE	omeprazole	70000-0356	HYPROMELLOSES
Cardinal Health	LEADER OMEPRAZOLE	omeprazole	70000-0356	LACTOSE MONOHYDRATE

Leader Omeprazole Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Leader Omeprazole is an OTC delayed-release omeprazole product positioned as a lower-cost private-label alternative to Prilosec OTC and other proton-pump inhibitor products. Its commercial value depends less on new-molecule exclusivity than on reliable enteric protection, low-cost pellet manufacturing, shelf-life performance, retailer access, and differentiated packaging or dosage formats.

The core excipient strategy is to protect acid-labile omeprazole until the product reaches the intestine. The most commercially relevant opportunities are private-label supply, retailer-exclusive packs, adherence-oriented packaging, pediatric and multiparticulate formats, and international products using the same enteric-pellet platform.

What is Leader Omeprazole?

Leader Omeprazole is generally marketed as an OTC 20 mg delayed-release capsule containing omeprazole, a proton-pump inhibitor used for the treatment of frequent heartburn. Leader is a private-label health-care brand associated with retailer and distributor channels rather than an originator pharmaceutical company.

Attribute	Product profile
Active ingredient	Omeprazole
Strength	Commonly 20 mg
Dosage form	Delayed-release capsule
Therapeutic class	Proton-pump inhibitor
Regulatory route	OTC product based on FDA requirements for omeprazole delayed-release products
Primary use	Frequent heartburn
Reference market	Prilosec OTC and generic omeprazole delayed-release products
Commercial channel	Retail pharmacy, mass merchandise, grocery, online and private-label distribution
Biosimilar exposure	None; omeprazole is a small molecule
Main technical challenge	Protecting omeprazole from gastric acid and moisture

The product should be evaluated as a formulation and supply-chain asset, not as a molecule protected by meaningful remaining compound exclusivity.

What excipients are used in Leader Omeprazole?

The exact inactive-ingredient composition depends on the manufacturer, strength, capsule shell, coating system and approved product label. Omeprazole delayed-release capsules commonly use multiparticulate pellets rather than a conventional immediate-release powder fill.

Typical excipient functions include:

Formulation function	Common excipient classes	Commercial purpose
Pellet core	Sugar spheres, microcrystalline cellulose or starch-based starter cores	Provides a uniform substrate for drug layering
Binder	Hypromellose, povidone or similar polymer	Holds omeprazole on the pellet surface
Alkaline stabilizer	Sodium hydroxide, disodium phosphate or other alkalizing agent	Reduces degradation caused by acidic microenvironments
Drug-layer vehicle	Hypromellose, sucrose or polymeric film former	Supports uniform drug deposition
Subcoating	Hypromellose, talc or protective polymer	Separates the drug layer from the enteric polymer
Enteric coating	Methacrylic acid copolymer, such as methacrylate-based polymer	Prevents release in the stomach
Plasticizer	Triethyl citrate or equivalent	Improves coating flexibility and reduces cracking
Anti-tacking agent	Talc or colloidal silicon dioxide	Controls pellet agglomeration during coating
Capsule shell	Gelatin or hydroxypropyl methylcellulose	Delivers the pellet dose
Colorants and opacifiers	Titanium dioxide and approved colorants	Supports product identification and light protection
Packaging desiccant	Silica gel or equivalent	Limits moisture-driven degradation

DailyMed should be used to confirm the inactive ingredients for the specific Leader NDC because private-label products can change manufacturers or suppliers without changing the consumer-facing brand name (U.S. National Library of Medicine, n.d.).

How does omeprazole’s chemistry determine excipient selection?

Omeprazole is acid-labile. Exposure to acidic conditions can cause degradation before the drug reaches the absorption site. The product therefore requires a dosage form that combines alkaline stabilization with delayed release.

The most robust architecture is:

1. An inert or low-reactivity pellet core.
2. An alkaline drug layer.
3. A protective subcoat.
4. An enteric polymer layer.
5. A hard capsule containing the coated pellets.

The alkaline microenvironment is central to performance. A coating that protects the capsule from gastric fluid but does not stabilize the drug during manufacture and storage will not provide adequate product quality. Formulators must control residual moisture, coating-bed temperature, aqueous-process exposure and the compatibility of the drug layer with the enteric polymer.

Excipient selection should prioritize:

• Low water activity.
• Limited acidic functionality near the drug layer.
• Stable supply of pharmaceutical-grade polymers.
• Consistent particle size and coating behavior.
• Compatibility with fluid-bed coating.
• Low extractables and leachables risk.
• Acceptable dissolution after exposure to gastric acid.
• Minimal capsule-shell cross-linking during storage.

What formulation patents protect omeprazole products?

The original commercial omeprazole estate included compound, formulation, process and therapeutic-use patents associated with AstraZeneca and its predecessor companies. The principal commercial patents expired years ago, and generic and private-label omeprazole products have been widely marketed.

IP category	Historical protection	Current commercial relevance
Omeprazole compound patents	Originator-era patents	Expired
Delayed-release pellet technology	Enteric protection, alkaline stabilization and multiparticulate delivery	Mostly expired or avoidable through alternative designs
Manufacturing processes	Drug layering, coating and drying processes	Often protected through know-how rather than enforceable blocking patents
Method-of-use patents	Heartburn and acid-related indications	Limited value for an OTC generic product
Packaging patents	Moisture-control and dispensing systems	Potentially relevant to differentiated products
New formulation patents	Pediatric, combination, modified-release or novel delivery formats	Potential opportunity if technical and clinical requirements are met

The key risk is not usually infringement of the historical omeprazole compound patent. It is freedom to operate around newer formulation patents, manufacturing improvements, device claims, trademark rights and regulatory exclusivity attached to a differentiated product.

When does omeprazole lose exclusivity?

Omeprazole’s core U.S. small-molecule exclusivity has expired. Generic omeprazole delayed-release capsules have competed for many years through abbreviated new drug applications, and OTC omeprazole products have faced broad competition from Prilosec OTC, store brands and online sellers.

Exclusivity element	Status
Active-ingredient exclusivity	Expired
Original prescription product exclusivity	Expired
OTC switch exclusivity	Expired
Generic competition	Established
Biosimilar pathway	Not applicable
Paragraph IV importance	Primarily historical for core omeprazole products
Remaining barriers	Manufacturing validation, supply reliability, formulation patents and retailer access

A current Leader product should not be valued on the assumption that it has molecule-level exclusivity. Its defensibility comes from cost, quality, supply continuity, channel placement and consumer recognition.

What is the Orange Book status of Leader Omeprazole?

Leader Omeprazole is generally a private-label OTC product rather than an innovator product with a stand-alone Orange Book patent estate. The Orange Book is principally relevant to approved drug applications and patent certifications associated with prescription and certain approved products. OTC private-label products may rely on an underlying approved application or regulatory pathway without creating a commercially meaningful patent position for the brand owner.

The relevant regulatory checks are:

• Whether the product is listed under an approved NDA or ANDA.
• Whether the marketed label matches the approved labeling.
• Whether the product is manufactured under the applicable OTC or approved-drug framework.
• Whether the manufacturer has current FDA registration and listing.
• Whether any patents are listed against the underlying application.
• Whether the Leader brand owner has rights to the product, label and packaging.

FDA’s Orange Book and Drugs@FDA records should be reviewed at the application level rather than assuming that the Leader trademark identifies the legal drug-application owner (FDA, 2024a; FDA, 2024b).

What manufacturing barriers affect Leader Omeprazole?

The main barrier is not API synthesis. It is reproducible multiparticulate processing.

Critical manufacturing steps include:

Drug layering

The manufacturer must deposit omeprazole uniformly on the pellet cores. Poor spray-rate control can produce wide pellet-to-pellet dose variation, agglomeration or incomplete coating.

Alkaline stabilization

The drug layer must maintain a sufficiently protective microenvironment. Excess alkalinity can create compatibility problems, while insufficient alkalinity can accelerate degradation.

Subcoating

The subcoat limits interaction between the omeprazole layer and the enteric polymer. It also reduces migration of soluble ingredients during aqueous coating.

Enteric coating

The coating must resist simulated gastric fluid and release the drug rapidly at intestinal pH. Overcoating can delay release and reduce bioavailability. Undercoating can cause premature release.

Moisture management

Moisture can reduce assay, increase degradation products and affect dissolution. Finished capsules should be placed in packaging with adequate moisture protection, often including a desiccant or high-barrier blister.

Capsule filling

Pellets must flow consistently and remain intact during filling. Excessive mechanical stress can fracture the enteric layer and alter dissolution.

These process controls can create a practical barrier to entry even when patent barriers are weak. A low-cost producer with unstable dissolution or short shelf life will face retailer returns, batch failures and loss of private-label contracts.

What commercial opportunities exist for Leader Omeprazole?

Retailer-exclusive private-label products

Omeprazole is suitable for store-brand programs because consumers understand the therapeutic category and compare products primarily on price, count size, retailer trust and availability. Opportunities include:

• 14-count packs for short-term self-care.
• 28- or 42-count packs for routine use.
• Club-store multipacks.
• E-commerce value bundles.
• Seasonal heartburn promotions.
• Retailer-exclusive capsule colors and packaging.

Contract manufacturing

The product can support contract-manufacturing arrangements based on a standardized coated-pellet platform. A manufacturer with validated omeprazole capacity can serve multiple brands while changing only the capsule shell, label and packaging configuration.

The strongest contract-manufacturing proposition combines:

• Existing FDA-compliant facilities.
• Fluid-bed coating capacity.
• Validated enteric dissolution methods.
• Multiple capsule and packaging lines.
• Redundant API and excipient suppliers.
• Demonstrated stability data.
• Capacity for short retail replenishment cycles.

Pediatric and multiparticulate products

Pediatric products are a potential growth area, but a child-friendly formulation requires more than placing pellets in a smaller capsule. Commercial options include:

• Sprinkle capsules.
• Packets containing enteric-coated granules.
• Oral suspensions prepared from protected multiparticulates.
• Unit-dose sachets.
• Flavored, age-appropriate presentations.

Taste masking must not compromise enteric protection. A liquid product also creates higher stability and preservative demands than a dry multiparticulate presentation.

Combination products

Potential combinations include omeprazole with antacids or other acid-control ingredients. These products face formulation and regulatory complications because the active ingredients may require different release profiles, pH environments and dosing instructions.

Combination products can raise average selling price, but they also increase:

• Labeling complexity.
• Stability testing requirements.
• Dose-ratio constraints.
• Manufacturing segregation requirements.
• Consumer-use and interaction questions.

Premium packaging

Packaging is one of the most accessible differentiation routes. Relevant options include:

• High-barrier blister packaging.
• Calendarized daily-dose packs.
• Child-resistant packaging.
• Travel packs.
• Adherence cards.
• Desiccant-integrated bottles.
• Recyclable or reduced-material packaging.

Packaging claims must remain consistent with FDA labeling and applicable environmental, child-safety and OTC requirements.

How does Leader Omeprazole compare with competing acid-reflux products?

Product class	Examples	Main advantage	Main limitation
Omeprazole	Leader Omeprazole, Prilosec OTC, store brands	Established PPI efficacy and broad consumer recognition	Delayed onset relative to antacids; enteric formulation required
Esomeprazole	Nexium 24HR and generics	Premium brand recognition and PPI positioning	Higher competition and potentially higher price
Lansoprazole	Prevacid 24HR and store brands	Established OTC PPI alternative	Smaller consumer mindshare in some channels
Famotidine	Pepcid AC and generics	Faster perceived relief and H2-blocker positioning	Different duration and mechanism
Calcium carbonate antacids	Tums and private labels	Rapid symptom relief and low unit cost	Shorter duration; no PPI-level acid suppression

Leader Omeprazole competes most directly with generic omeprazole and store-brand PPIs. The main competitive variables are retail price, count size, product availability, consumer reviews, brand trust and the manufacturer’s ability to maintain supply.

Which companies are challenging the omeprazole market?

Competition comes from several groups:

• AstraZeneca and successor commercial organizations associated with Prilosec.
• Generic drug manufacturers supplying omeprazole delayed-release capsules.
• OTC private-label manufacturers.
• Retail pharmacy chains.
• Mass merchants and warehouse clubs.
• Online marketplace sellers.
• Manufacturers of esomeprazole, lansoprazole and famotidine products.

Because the market is mature, competitive advantage depends on operating economics. A supplier with lower coating costs, fewer batch failures and reliable API sourcing can win contracts even without differentiated patent rights.

What generic entry risks exist for Leader Omeprazole?

Leader Omeprazole has high substitution risk because:

• The active ingredient is off-patent.
• Multiple generic and store-brand products are available.
• Consumers can switch based on price.
• Retailers can replace suppliers with limited customer disruption.
• The dosage form is standardized.
• Product claims are closely constrained by OTC labeling.

The largest commercial risks are price compression, private-label cannibalization, retailer delisting, manufacturing interruption and quality-related recalls. A formulation change that alters dissolution, capsule appearance or inactive ingredients can also create consumer and regulatory risk.

How strong is the patent estate for Leader Omeprazole?

The patent estate is weak at the molecule level and potentially moderate at the formulation or process level.

Asset	Relative strength
Omeprazole active ingredient	Low
Standard 20 mg delayed-release capsule	Low
Conventional enteric-coated pellets	Low to moderate
Proprietary coating process	Moderate if difficult to design around
Pediatric multiparticulates	Potentially moderate
Combination product	Potentially moderate
Packaging and dispensing system	Moderate in a narrow field
Manufacturing know-how	Commercially meaningful but not necessarily patent-protected

The strongest defensible assets are likely to be regulatory execution, manufacturing know-how, supplier qualification, packaging design and retailer relationships rather than broad composition-of-matter claims.

What revenue exposure does Leader Omeprazole create?

Revenue exposure depends on the customer contract and channel mix. A store-brand omeprazole product can generate recurring volume but usually operates under pricing pressure. Margin is influenced by:

• API cost.
• Pellet-coating yield.
• Enteric polymer consumption.
• Capsule-shell cost.
• Packaging format.
• Batch size.
• Retailer deductions.
• Freight and inventory requirements.
• Returns and expiry allowances.

A 14-count package may maximize trial and promotional flexibility. Larger packs can reduce packaging and distribution costs per dose but expose the supplier to slower inventory turns and greater retailer price competition.

What regulatory status applies to omeprazole OTC products?

FDA OTC omeprazole products are subject to requirements covering active ingredients, labeling, dosage, warnings, directions, quality and manufacturing. A manufacturer must support the product through the applicable FDA pathway and maintain compliance with current good manufacturing practice requirements.

Key regulatory obligations include:

• Identity, strength, quality and purity testing.
• Assay and degradation-product controls.
• Acid-resistance and dissolution testing.
• Stability testing in the proposed package.
• Capsule and pellet uniformity.
• Microbial and moisture controls.
• Labeling compliance.
• Change-control documentation.
• Supplier qualification and traceability.

OTC status does not eliminate CMC risk. The delayed-release performance of the dosage form remains a critical quality attribute.

Key Takeaways

1. Leader Omeprazole is a mature OTC private-label product centered on a 20 mg delayed-release omeprazole capsule.
2. The key excipient objective is to stabilize acid-labile omeprazole and prevent gastric release.
3. A multiparticulate pellet system using alkaline stabilization, subcoating and enteric coating is the dominant technical strategy.
4. Core omeprazole patents and exclusivities have expired; commercial defensibility comes from manufacturing, quality, packaging, supply and retail access.
5. The strongest opportunities are private-label expansion, contract manufacturing, pediatric multiparticulates, adherence packaging and retailer-exclusive formats.
6. The largest risks are price compression, supplier substitution, dissolution failure, moisture degradation, recalls and retailer delisting.
7. Biosimilar risk does not apply because omeprazole is a small-molecule drug.
8. Exact Leader inactive ingredients and legal application ownership must be evaluated against the current product label and FDA listing for the relevant NDC.

FAQs About Leader Omeprazole Excipient Strategy

Is Leader Omeprazole the same drug as Prilosec OTC?

Yes. Products marketed as omeprazole delayed-release capsules contain the same active ingredient, although inactive ingredients, capsule design, manufacturing site and packaging can differ.

Why does Leader Omeprazole use delayed-release pellets?

The pellets prevent omeprazole from releasing in the stomach, where acid can degrade the drug. The enteric coating is designed to dissolve at a higher intestinal pH.

Can Leader Omeprazole be reformulated as a tablet?

Yes, but the tablet would still require a reliable acid-protection system. A tablet may use enteric-coated granules, an enteric film or another multiparticulate architecture.

Which excipient is most important in omeprazole products?

No single excipient determines performance. The combination of an alkaline stabilizing environment, protective subcoat and enteric polymer is the critical formulation system.

Is an omeprazole private-label product protected by a strong patent estate?

Usually not at the active-ingredient level. Any meaningful protection is more likely to arise from a specific formulation, manufacturing process, packaging system or proprietary regulatory asset.

References

1. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024b). Drugs@FDA data files and drug databases. https://www.fda.gov/drugs/drug-approvals-and-databases

3. U.S. National Library of Medicine. (n.d.). DailyMed: Omeprazole delayed-release capsule labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2024c). Current good manufacturing practice requirements for finished pharmaceuticals. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.